Skip to main content
main-content

Lymphoma

Lymphoma

15-05-2018 | Oncology | News | Article

Tisagenlecleucel approved for relapsed, refractory DLBCL

Read more on this CAR T-cell therapy announcement here

04-05-2018 | Oncology | News | Article

In other news

This month we bring you a round-up of four trials investigating nivolumab in diverse tumors, including non-small-cell lung cancer, Hodgkin lymphoma, and nasopharyngeal carcinoma. Read on to find out more.

10-04-2018 | Lymphoma | News | Article

Ibrutinib, venetoclax oral combination shows promise for mantle cell lymphoma

Ibrutinib plus venetoclax could together be beneficial as oral treatment for mantle-cell lymphoma, suggests a phase II study published in The New England Journal of Medicine.

22-03-2018 | Oncology | Main feed | News

First-line brentuximab vedotin approved for advanced Hodgkin lymphoma

Read more on this US FDA announcement here

02-03-2018 | Oncology | News | Article

Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

The phosphatidylinositol 3-kinase isoform p110δ inhibitor umbralisib has shown preliminary activity against relapsed or refractory hematologic malignancies, with fewer autoimmune-like toxicities than other drugs in its class, researchers report.

08-01-2018 | Lymphoma | News | Article

Anaplastic large-cell lymphoma risk with breast implants determined

Silicone-filled breast implants are associated with a high relative risk for developing anaplastic large-cell lymphoma in the breast, but the absolute risk remains low, confirms a population-based study.

22-12-2017 | Lymphoma | News | Article

CAR T-cell therapy effective for refractory large B-cell lymphomas

The results of two studies published in The New England Journal of Medicine support the use of autologous chimeric antigen receptor T cells directed against CD19 in patients with relapsed or refractory B-cell lymphomas.

19-12-2017 | Lymphoma | News | Article

Acalabrutinib monotherapy promising for relapsed, refractory mantle cell lymphoma

Treatment with the second-generation Bruton tyrosine kinase inhibitor acalabrutinib induces durable responses in patients with relapsed or refractory mantle cell lymphoma, indicates the phase II ACE-LY-004 trial.

12-12-2017 | Lymphoma | News | Article

Brentuximab vedotin may improve outcome in advanced Hodgkin lymphoma

A treatment regimen incorporating the anti-CD30 antibody–drug conjugate brentuximab vedotin is more effective than standard therapy with doxorubicin, bleomycin, vinblastine, and dacarbazine when used as a frontline therapy in patients with advanced Hodgkin lymphoma, phase III trial data show.

23-11-2017 | Oncology | News | Article

FDA announces approvals for sunitinib, obinutuzumab

More details on these decisions are a click away

06-11-2017 | Oncology | News | Article

Acalabrutinib receives FDA go-ahead for mantle cell lymphoma

Click through to read more on this accelerated approval

01-11-2017 | Lymphoma | News | Article

Breast implant-associated lymphoma characterized

US researchers have detailed the pathophysiology, clinical presentation, and management of breast implant-associated anaplastic large cell lymphoma in a move to educate healthcare professionals dealing with this rare but increasingly common diagnosis.

31-10-2017 | Lymphoma | News | Article

PET-guided treatment de-escalation feasible in Hodgkin lymphoma

A negative positron emission tomography scan after initial treatment with BEACOPP in escalated doses identifies Hodgkin lymphoma patients suitable for a reduction in the total number of cycles needed, HD18 trial data show.

10-10-2017 | Lymphoma | News | Article

Post-HSCT maintenance rituximab improves mantle-cell lymphoma survival

Maintenance treatment with the anti-CD20 antibody rituximab after induction immunochemotherapy and autologous hematopoietic stem-cell transplantation is associated with a significant survival benefit among young patients with mantle-cell lymphoma, phase III trial findings show.

06-10-2017 | Lymphoma | News | Article

Obinutuzumab may improve follicular lymphoma outcome

Treatment with obinutuzumab-based chemotherapy prolongs progression-free survival over rituximab-based therapy in patients with follicular lymphoma, GALLIUM trial data suggest.

20-09-2017 | Lymphoma | Main feed | News

Copanlisib, low-dose cabazitaxel receive FDA go ahead

Click through to read more on these approvals

24-08-2017 | Oncology | News | Article

Crizotinib shows promise in pediatric ALCL and IMT

Pediatric patients with anaplastic large cell lymphomas and inflammatory myofibroblastic tumors respond well to crizotinib therapy, with more than 80% experiencing an objective response, US researchers report.

07-07-2017 | Lymphoma | Main feed | News

Rituximab–hyaluronidase human combination approved for multiple indications

Click through to read a round-up of recent US FDA approvals

19-05-2017 | Oncology | News | Article

In other news

Here we report on osteoporosis therapy in breast cancer patients, the feasibility of an alternative formulation of rituximab in follicular lymphoma, the effects of extended use of anamorelin on lung cancer-related cachexia, and the 3-year results of the COMBI-d trial.

04-05-2017 | Lymphoma | News | Article

Lenalidomide maintenance delays disease progression in DLBCL

Lenalidomide maintenance therapy significantly improves progression-free survival in elderly patients with diffuse large B-cell lymphoma who respond to first-line chemotherapy, phase III trial data show.

Image Credits